March 2026- Bayer has received approval from the European Commission to expand the use of Kerendia™ (finerenone) across the European Union for adults living with certain types of heart failure. The decision allows the drug, a selective non-steroidal mineralocorticoid receptor antagonist, to be prescribed for patients with left ventricular ejection fraction of 40 percent or higher, including those with mildly reduced or preserved ejection fraction.

With this approval, Kerendia in 10 mg, 20 mg, and 40 mg doses is now indicated for treating symptomatic chronic heart failure in adults within this category. The move broadens the medication’s scope beyond its earlier use for patients with chronic kidney disease linked to type 2 diabetes, marking a significant step in its clinical application.

Click here to join our WhatsApp channel here

“Patients with heart failure with left ventricular ejection fraction of 40% or greater represent a large and growing group of patients with a poor prognosis who face substantial clinical challenges including repeat hospitalizations for worsening heart failure, and high mortality risk,” said Scott D. Solomon, MD, Professor of Medicine, Harvard Medical School, Director, Clinical Trials Outcomes Center, Mass General Brigham, and Chair of the study’s Executive Committee.

“The approval of the new indication for Kerendia in the EU is excellent news for millions of patients in Europe with heart failure and left ventricular ejection fraction of ≥40%. We are committed to ensuring that eligible patients have access to this important new treatment option to improve their outcomes,” said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer.

Also read: Novo Nordisk Secures FDA Approval for Once-Weekly Basal Insulin Awiqli®